Examination of the treatment prediction factor of Ledipasvir/Sofosbuvir in chronic hepatitis C of Genotype1b.

Examination of the treatment prediction factor of Ledipasvir/Sofosbuvir in chronic hepatitis C of Genotype1b. - Examination of the treatment prediction factor of Ledipasvir/Sofosbuvir in chronic hepatitis C of Genotype1b.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027860

Enrollment

700

Registered

2017-06-22

Start date

2017-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis C who treat with Ledipasvir/Sofosbuvir combination therapy.

Exclusion criteria

Exclusion criteria: Patient who did not obtain consent to use the data.

Design outcomes

Primary

Measure	Time frame
Sustained virological response rate	—

Secondary

Measure	Time frame
1. Change in serum HCV RNA during treatment and follow-up duration 2. Change in hematological and biochemical test during treatment and follow-up duration 3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration.	—

Countries

Japan

Contacts

Public ContactMasanori Atsukawa

Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

atsukawa-nms@umin.ac.jp0476-99-1111

Outcome results